scholarly journals Clinicopathologic Aspects of Squamous Cell Carcinoma of the Uterine Cervix: Role of PTEN, BCL2 and P53

2018 ◽  
Vol 8 (11) ◽  
pp. 2124 ◽  
Author(s):  
Ali Babiker ◽  
Ahmad Almatroudi ◽  
Khaled Allemailem ◽  
Nazik Husain ◽  
Mohamed Alsammani ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Uterine Cervix ◽  
P53 Protein ◽  
Clinical Stage ◽  
Pten Expression ◽  
Cancer Tissue ◽  
Inflammatory Lesions

Background: Squamous cell carcinoma (SCC) of the uterine cervix is a leading cause of morbidity and mortality among women. The alterations of Phosphatase and tensin homolog (PTEN), B-cell lymphoma 2 (Bcl2) and p53 expression seem to be significant in the development of various types of cancers. The altered expressions of PTEN, Bcl2 and p53 and their involvement in cancer of the uterine cervix are not well recognized. Aim: This study aimed at examining the expression patterns of PTEN, Bcl2 and p53 proteins and comparing them with the grade and stage of cervical cancer. Materials and Methods: Tissue blocks of SCC and ten cases of inflammatory lesions of the uterine cervix were examined immunohistochemically for the expression of PTEN, Bcl2 and p53 proteins. Results: Loss of PTEN expression was identified in 45.33% of cervical SCC and no expression was found in inflammatory lesions (p ≤ 0.05). PTEN expression was significantly associated with the clinical stage of SCC (61.36% and 45.16% in stages I–II and III–IV, respectively) (p < 0.05), but not with the degree of differentiation of the SCC. The expression of Bcl2 was significantly high (60%) in cancer cases than in control cases (p < 0.05). Bcl2 did not show any significant association with the histologic type and clinical stage of the SCC of the uterine cervix. The expression of p53 protein was significantly high (57.33%)) in cancer tissue, and no expression was noted in control cases (p < 0.05). Moreover, the expression pattern of p53 protein in cervical cancer tissue samples was not linked with the patient age, grade and stage of the cervical SCC (p > 0.05). Conclusion: The reduced expression of PETN and overexpressions of Bcl2 and p53 might play an indispensable role in carcinogenesis of cervical SCC. Moreover, a relationship was detected between PTEN expression and clinical stage of the cervical SCC.

Changing Incidence of Invasive Adenocarcinoma of the Uterine Cervix in East Anglia

1997 ◽  
Vol 4 (1) ◽  
pp. 40-43 ◽  
Author(s):  
Diane Stockton ◽  
Pauline Cooper ◽  
R N Lonsdale
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Birth Cohort ◽  
Squamous Cell ◽  
Uterine Cervix ◽  
Invasive Adenocarcinoma ◽  
East Anglia ◽  
The Mean ◽  
Age Shift

Objective— To determine trends in incidence of invasive adenocarcinoma of the uterine cervix in East Anglia. Methods— Cervical cancer incidence data for both squamous cell carcinomas and adenocarcinomas were obtained from the East Anglian Cancer Registry for the period 1971–94. Similar data were obtained for England and Wales. European age standardised rates (ASRs) were used for comparisons. Results— The mean incidence (ASR) of cervical adenocarcinoma was 0.85 per 10s in 1971–76, rising to 2.54 per 105 in 1989–94. There has been a marked age shift, with the main increase in incidence occurring in younger women aged 30–39. The mean incidence (ASR) of squamous cell carcinoma of the cervix has decreased from 9.78 to 8.74 per 10s over the periods 1971–76 and 1989–94. Again there has been an age shift, moving from a single incidence peak in the 4S-S9 age band in earlier years to incidence peaks in both the 30–39 and 55–69 age bands in more recent years. Similar trends were noted when data for England and Wales were analysed. Birth cohort analyses show that both tumours are occurring progressively earlier (about five years earlier in each five year birth cohort). Conclusion— Although the overall incidence of cervical carcinoma is declining, this study has shown an increased incidence of cervical adenocarcinoma, particularly in the younger age groups. In future it would seem advisable to publish separate incidence and mortality data for squamous cell carcinoma and adenocarcinoma of the uterine cervix. All practitioners involved in the cervical cancer screening programme would then be aware of the very real significance of this tumour.

scholarly journals Immunohistochemical Expression of p53 and Bcl-2 in Algerian Cervical Carcinoma

2018 ◽  
Vol 11 (1) ◽  
pp. 67-75
Author(s):  
Deffar Khalissa ◽  
Khenchouche Abdelhalim ◽  
Xing Xie ◽  
Ying Li ◽  
Ouhida Soraya ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Prognostic Marker ◽  
Uterine Cervix ◽  
Prognostic Markers ◽  
P53 Protein ◽  
Immunohistochemical Expression ◽  
Important Indicator ◽  
P53 Expression

The Objective of the present study is to evaluate the expression levels of Bcl-2 and p53 proteins in squamous cell carcinoma and adenocarcinoma of the uterine cervix, and try to explain their role as prognostic markers for this cancer. The cohort comprised 90 cases of the cervix lesions. The samples were assessed by immunohistochemistry for the expression of Bcl-2 and p53 proteins. The results showed that the Bcl-2 expression was either absent, low or moderate respectively in 38.96%; 50.65% and 10.39% of SCC cases. However, it was absent or expressed in 76.92% and 23.08% of adenocarcinoma cases respectively. The p53 protein was absent or present respectively in 75.32% and 24.68% of SCC cases as demonstrated by immunohistochemistry. p53 was almost absent in adenocarcinoma samples where only 7.70% of cases were positive. There was no significant correlation between Bcl-2 and p53 expression (p=0.352). We conclude that p53 expression, detected by immunohistochemistry, does not appear to be a prognostic marker for cervical cancer. Nevertheless, Bcl-2 expression seems to provide more information for this disease. It may represent an important indicator for cervical cancer.

Squamous Cell Carcinoma Antigen for Monitoring Cervical Cancer

1988 ◽  
Vol 3 (2) ◽  
pp. 87-94 ◽  
Author(s):  
P. Schmidt-Rhode ◽  
K.D. Schulz ◽  
G. Sturm ◽  
H. Häfner ◽  
H. Prinz ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Uterine Cervix ◽  
Primary Treatment ◽  
Pelvic Lymphadenectomy ◽  
Treatment Modalities ◽  
Early Rise ◽  
Scc Antigen

The tumour-associated antigen was determined in the plasma of patients with squamous cell carcinoma (SCC) of the uterine cervix by radioimmunoassay. Setting a limit of 2 ng/ml, levels were abnormal in 13.4% of healthy controls, in 14% of patients with carcinoma in situ and in 62% of patients with invasive cervical SCC. The incidence of elevated SCC antigen levels and the absolute antigen plasma concentration were dependent upon the tumour load, increasing significantly with advanced stage disease. Abnormal SCC antigen values in operable cervical cancer declined to normal within one week after radical hysterectomy with pelvic lymphadenectomy. In cases of radiotherapy antigen values took 4-6 weeks after the start of treatment to return to normal. The success of both treatment modalities was announced by an early rise in the SCC antigen in the initial phase of therapy, followed by normalisation. After successful primary treatment and a complete remission during further follow-up SCC antigen in plasma was only increased in 3.8% of the cases. Retrospective evaluations in ten patients with progressive disease showed the reappearance of abnormal SCC titers and further increase preceeding the clinically detectable relapse or progression, with a median interval of 8 weeks. The present study indicates that SCC antigen determination is not useful for the early diagnosis of cervical cancer, but it is a potential means for monitoring the efficacy of individual anticancer therapy of SCC of the uterine cervix and for detecting recurrent disease.

scholarly journals PROFILE OF HISTOPATHOLOGY OF CERVICAL CANCER TISSUES IN PATIENTS OF THE DR PIRNGADI MEDAN HOSPITAL

2020 ◽  
Vol 6 (3) ◽  
pp. 90
Author(s):  
Sry Astuty Hasugian ◽  
Khairiza Lubis ◽  
Hau V Doan
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Squamous Cell ◽  
Adenosquamous Carcinoma ◽  
Malignant Neoplasm ◽  
Cancer Tissue ◽  
Pathology Laboratory ◽  
Cervical Cancer Tissue

Cervical cancer is a malignant neoplasm that happened in the cervical area.  Several types of cervical cancer that usually happens in women such as squamous cell carcinoma (SCC), adenocarcinoma, adenosquamous carcinoma and neuroendocrine carcinoma. Therefore, this study aims to determine a descriptive description of the histopathological profile of cervical cancer tissue from patients that registered in the Anatomical Pathology Laboratory at the DR. Pirngadi Medan Hospital, in the period of 2019. The type of our research is retrospective descriptive with the sampling technique, namely total sampling. The sample used was cervical cancer tissue obtained from the biopsy and surgery on patients who were registered from January 2019 to December 2019, totaling 18 samples. Based on the descriptive histopathological description, we found three types of cervical cancer tissue: squamous cell carcinoma (55.5%), adenocarcinoma (38.8%) and adenosquamous carcinoma (5.5%). The neuroendocrine carcinoma type did not find in this present study. Of three types of these cervical cancer, we got that cervical cancer patients are women aged between 36-72 years, with an average age of 54 years.

Endometrial extension of adenosquamous carcinoma of the uterine cervix

2004 ◽  
Vol 14 (4) ◽  
pp. 625-627 ◽  
Author(s):  
Y. Nakao ◽  
M. Yokoyama ◽  
K. Hara ◽  
M. Yasunaga ◽  
M. Uchiyama ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Uterine Cervix ◽  
Adenosquamous Carcinoma ◽  
Uterine Cavity ◽  
First Case ◽  
Related Category

Endometrial in situ extension of cervical cancer is extremely uncommon. Previous reports only present the cases of squamous cell carcinoma or related category. This report presented adenosquamous carcinoma of the uterine cervix that showed a paradoxical extension of each component in a 72-year-old patient. Main tumor in the cervix was revealed to be adenosquamous carcinoma. The glandular component extended to the vagina, while the squamous component grew into the entire uterine cavity and replaced the glandular epithelium. We presented the first case of adenosquamous carcinoma of the uterine cervix with vaginal and endometrial extension. Furthermore, the endometrium was replaced with squamous component, while the vagina was invaded by glandular component. The observed paradoxical extension of the present case was extremely rare.

Evaluation of Serum Human Telomerase Reverse Transcriptase as a Novel Marker for Cervical Cancer

2011 ◽  
Vol 26 (1) ◽  
pp. 22-26 ◽  
Author(s):  
Mahendar Porika ◽  
Radhika Tippani ◽  
Anwar Mohammad ◽  
Sekhar R Bollam ◽  
Sree D Panuganti ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Reverse Transcriptase ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Clinical Stage ◽  
Ca 125 ◽  
Telomerase Reverse Transcriptase ◽  
Human Telomerase Reverse Transcriptase ◽  
Human Telomerase

Human telomerase reverse transcriptase (hTERT) is the catalytic subunit of human telomerase and its rate-limiting component. The purpose of the present study was to investigate the diagnostic value of hTERT in serum of cervical cancer patients. Preoperative values of hTERT, squamous cell carcinoma antigen (SCC-ag) and cancer antigen 125 (CA 125) were measured by enzyme-linked immunosorbent assay (ELISA) in 192 patients with squamous cell carcinoma or adenocarcinoma of the uterine cervix and 38 healthy controls. Elevated pretreatment levels of hTERT were identified in 80.2% of squamous cell carcinoma and 73.8% of adenocarcinoma patients. The expression of serum hTERT was correlated with telomerase activity in cancer tissues of both histological types. Pretreatment serum hTERT levels showed a significant correlation with clinical stage, tumor size and lymph node metastasis, but not with age. Serum hTERT measurement was found to be useful in the diagnosis and assessment of clinical stage of cervical cancer, and to be superior to the conventional tumor markers. Therefore, serum hTERT is a novel and readily available marker for cervical malignancies.

Sign in / Sign up

Export Citation Format

Share Document